The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year. The study found that if HIV-infected heterosexual individuals begin taking antiretroviral medicines when their immune systems are relatively healthy as opposed to delaying therapy until the disease has advanced, they are 96 percent less likely to transmit the virus to their uninfected partners.
Tags: Articles, News, Sexually Transmitted Diseases, Std
This entry was posted
on Friday, December 23rd, 2011 at 9:41 am and is filed under STDs.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year. The study found that if HIV-infected heterosexual individuals begin taking antiretroviral medicines when their immune systems are relatively healthy as opposed to delaying therapy until the disease has advanced, they are 96 percent less likely to transmit the virus to their uninfected partners.
This entry was posted
on Friday, December 23rd, 2011 at 9:41 am and is filed under Sexual Health.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
